Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLiontrust Asset Management Regulatory News (LIO)

Share Price Information for Liontrust Asset Management (LIO)

Share Price is delayed by 15 minutes
Get Live Data
310.50    0.00 (0.00%)
Bid:
309.50
Ask:
311.50
Spread: 2.00 (0.646%)
Market Cap: £185.64m
LIO Live PriceLast checked at - London Stock Exchange

Intraday Liontrust Asset Management Share Chart

Statement re update on documents publication

9 Jun 2023 07:00

RNS Number : 1780C
Liontrust Asset Management PLC
09 June 2023
 

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

LEI: 549300XVXU6S7PLCL855

 

For immediate release

9 June 2023

 

Liontrust Asset Management Plc

("Liontrust" or the "Company")

Update on publication of documents for Proposed Acquisition

 

Further to the announcement by Liontrust dated 4 May 2023 in relation to the proposed acquisition of the entire issued share capital of GAM Holding AG ("GAM"), a global investment management group (the "Proposed Acquisition"), Liontrust provides an update on publication of the circular in relation to the Proposed Acquisition (the "Circular") and the Swiss offer prospectus setting out the terms and conditions of the Proposed Acquisition to the GAM shareholders (the "Swiss Offer Prospectus").

 

The Company had previously stated that it intended to publish the Circular and Swiss Offer Prospectus on 9 June 2023. The Board now expects to publish both the Circular and Swiss Offer Prospectus on or around 13 June 2023.

 

 

For further information please contact:

 

Teneo (Tel: 020 7353 4200, Email: liontrust@teneo.com)

Tom Murray or Stephanie Mackrell

 

Liontrust Asset Management Plc (Tel: 020 7412 1700, Website: liontrust.co.uk)

John Ions: Chief Executive

Vinay Abrol: Chief Financial Officer & Chief Operating Officer

Simon Hildrey: Chief Marketing Officer

David Boyle: Head of Corporate Development

 

Alantra Corporate Finance LLP (Tel: 020 7246 0500)

Lead Financial Adviser

JP McGrath, Jake Delaney, André Chetty

 

Singer Capital Markets Advisory LLP (Tel: 020 7496 3000)

Sole Sponsor, Financial Adviser and Sole Broker

Stephen Howard, Tom Salvesen, Justin McKeegan, Asha Chotai

 

Panmure Gordon (Tel: 020 7886 2500)

Corporate Broking: Stephen Jones

Corporate Advisory: Dominic Morley

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRKVLFBXQLLBBF
Date   Source Headline
2nd Feb 20267:05 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSTransaction in Own Shares
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20263:22 pmRNSForm 8.3 -KITWAVE GROUP PLC
29th Jan 20263:19 pmRNSForm 8.3 - Auction Technology Group
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20262:45 pmRNSForm 8.3 - Oxford Biomedica Plc
28th Jan 20262:40 pmRNSForm 8.3 - Kitwave Group Plc
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20263:25 pmRNSForm 8.3 - Auction Technology Group Plc
26th Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20262:08 pmRNSForm 8.3 - Oxford Biomedica Plc
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20264:40 pmRNSForm 8.3 - Auction Technology Group PLC
14th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTrading Statement
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20263:17 pmRNSDirector/PDMR Shareholding
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20263:29 pmRNSHolding(s) in Company
2nd Jan 202611:08 amRNSTotal Voting Rights
23rd Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20254:00 pmRNSDirector/PDMR Shareholding
19th Dec 20254:00 pmRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20255:44 pmRNSForm 8.3 - INSPECS GROUP PLC
12th Dec 20255:27 pmRNSForm 8.3 - INSPECS GROUP PLC
11th Dec 20251:42 pmRNSForm 8.3 - INSPECS GROUP PLC
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20253:03 pmRNSForm 8.3 - INSPECS GROUP PLC
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20253:36 pmRNSForm 8.3 - INSPECS GROUP PLC
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20254:02 pmRNSForm 8.3 - ESSENSYS PLC
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20252:23 pmRNSForm 8.3 - INSPECS GROUP PLC
2nd Dec 20251:19 pmRNSForm 8.3 - INSPECS GROUP PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.